Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 5 | Duke UniversityOTHER | 1 | Jul 15, 2015 | clinicaltrials |
| NCT00905398 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(ALLPhi) | terminated | Phase 1 / Phase 2 | 8 | Rony SchaffelOTHER | 0 | Jul 9, 2015 | clinicaltrials |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | terminated | Phase 2 | 4 | Valerio TherapeuticsINDUSTRY | 1 | Jul 8, 2015 | clinicaltrials |
| NCT00413478 | 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | terminated | Phase 3 | 48 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2015 | clinicaltrials |
| NCT00771602 | Alemtuzumab + Rituximab Consolidation in CLL | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01397149 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | terminated | Phase 1 / Phase 2 | 4 | University of UlmOTHER | 2 | May 28, 2015 | clinicaltrials |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | terminated | Phase 1 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 27, 2015 | clinicaltrials |
| NCT01463852 | A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Early Phase 1 | 11 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 6 | University of ArkansasOTHER | 1 | Apr 6, 2015 | clinicaltrials |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | terminated | Phase 2 | 12 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00748631 | Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.(KYPHOK) | terminated | N/A | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 24, 2015 | clinicaltrials |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00005834 | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | terminated | Phase 3 | 19 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00891033 | Panobinostat/Velcade in Multiple Myeloma | terminated | Phase 1 | 12 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT01449539 | Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization | terminated | N/A | 8 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | NYU Langone HealthOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | terminated | Phase 2 | 40 | King's College Hospital NHS TrustOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01537861 | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | terminated | Early Phase 1 | 7 | Washington University School of MedicineOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00060671 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | terminated | Phase 3 | 800 | CTI BioPharmaINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT01465230 | Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia | terminated | Phase 2 | 2 | Yale UniversityOTHER | 1 | Oct 23, 2014 | clinicaltrials |
| NCT01653418 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation(V-BEAM) | terminated | Phase 2 | 10 | Washington University School of MedicineOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | terminated | N/A | 10 | Indiana UniversityOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | BiogenINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00240162 | PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma | terminated | Phase 2 | 21 | Washington University School of MedicineOTHER | 1 | Sep 17, 2014 | clinicaltrials |
| NCT01914718 | Dose-adjusted EPOCH-R in MYC Positive DLBCL | terminated | Phase 2 | 26 | Fudan UniversityOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT01301963 | Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide | terminated | Phase 3 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 30, 2014 | clinicaltrials |
| NCT01534949 | Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial(Triad-DLBCL) | terminated | Phase 1 | 1 | CelltrionINDUSTRY | 1 | Jul 23, 2014 | clinicaltrials |
| NCT01466868 | Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma(AKTIL) | terminated | Phase 2 | 22 | Centre Leon BerardOTHER | 1 | Jul 10, 2014 | clinicaltrials |
| NCT02079519 | A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma | terminated | Phase 2 | 10 | Hoffmann-La RocheINDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00872300 | PHA-739358 for the Treatment of Multiple Myeloma | terminated | Phase 2 | 7 | Nerviano Medical SciencesINDUSTRY | 2 | May 28, 2014 | clinicaltrials |
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 27 | Pharmacyclics LLC.INDUSTRY | 1 | May 23, 2014 | clinicaltrials |
| NCT00183950 | Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy | terminated | Phase 1 / Phase 2 | 12 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183976 | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas | terminated | Phase 2 | 15 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183989 | Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma | terminated | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00383565 | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2015source: clinicaltrials